Akari Therapeutics exploring pivotal trial designs for nomacopan for BP
The company said, "Phase II trial results with nomacopan were presented at the 28th European Academy of Dermatology and Venereology Congress on October 10, 2019. Four of the six patients were classified as at the upper limit of moderate BP. The four patients saw a rapid and significant improvement in symptoms, with a mean 63% decline in Bullous Pemphigoid Disease Area Index score and mean 68% decline in blister score by day 42, with either no or minimal early steroid treatment. The data showed nomacopan's potential as monotherapy with the additional potential benefit of reducing steroid use which has multiple adverse effects. During the third quarter of 2019, the FDA granted orphan drug designation for nomacopan for the treatment of BP. The company is now exploring pivotal trial designs."